In the present study, we developed a simple and easily applicable scoring system based on serological AFP and NLR to predict treatment response and survival outcomes in patients with unresectable HCC undergoing immunotherapy with ICIs. This evidence concerns the gene AFP and hepatocellular carcinoma.